Replies to post #92005 on $heff's $tation of $tocks & $olid DD

[read_this_n0w]

PTC Therapeutics has positive read through from EMA agenda, says Oppenheimer
After European drug regulator EMA published its draft agenda for a December 14-17 meeting, Oppenheimer says the agenda indicates that the agency will decide whether to adopt the company's Translama drug, rather than consider evidence about it or just discuss it. The firm thinks the agency could release a positive opinion about the drug sooner than expected. It keeps a $135 price target and Outperform rating on the shares